scholarly journals Expression of somatostatin receptors 2 and 5 in circulating tumour cells from patients with neuroendocrine tumours

2016 ◽  
Vol 115 (12) ◽  
pp. 1540-1547 ◽  
Author(s):  
Alexa Childs ◽  
Clare Vesely ◽  
Leah Ensell ◽  
Helen Lowe ◽  
Tu Vinh Luong ◽  
...  
Keyword(s):  
Neuroendocrine Tumours ◽  
Somatostatin Receptors ◽  
Tumour Cells ◽  
Circulating Tumour Cells

scholarly journals Circulating tumour cells and their association with bone metastases in patients with neuroendocrine tumours

2019 ◽  
Vol 120 (3) ◽  
pp. 294-300 ◽  
Author(s):  
Francesca M. Rizzo ◽  
Clare Vesely ◽  
Alexa Childs ◽  
Teresa Marafioti ◽  
Mohid S. Khan ◽  
...  
Keyword(s):  
Bone Metastases ◽  
Neuroendocrine Tumours ◽  
Tumour Cells ◽  
Circulating Tumour Cells

scholarly journals 177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition

2019 ◽  
Vol 26 (4) ◽  
pp. 437-449 ◽  
Author(s):  
Tobias Hofving ◽  
Viktor Sandblom ◽  
Yvonne Arvidsson ◽  
Emman Shubbar ◽  
Gülay Altiparmak ◽  
...  
Keyword(s):  
Neuroendocrine Tumours ◽  
Somatostatin Receptor ◽  
Somatostatin Receptors ◽  
Xenograft Model ◽  
Progression Free Survival ◽  
Tumour Volume ◽  
Tumour Cells ◽  
Hsp90 Inhibition ◽  
Killing Effect

177Lu-octreotate is an FDA-approved radionuclide therapy for patients with gastroenteropancreatic neuroendocrine tumours (NETs) expressing somatostatin receptors. The 177Lu-octreotate therapy has shown promising results in clinical trials by prolonging progression-free survival, but complete responses are still uncommon. The aim of this study was to improve the 177Lu-octreotate therapy by means of combination therapy. To identify radiosensitising inhibitors, two cell lines, GOT1 and P-STS, derived from small intestinal neuroendocrine tumours (SINETs), were screened with 1224 inhibitors alone or in combination with external radiation. The screening revealed that inhibitors of Hsp90 can potentiate the tumour cell-killing effect of radiation in a synergistic fashion (GOT1; false discovery rate <3.2 × 10−11). The potential for Hsp90 inhibitor ganetespib to enhance the anti-tumour effect of 177Lu-octreotate in an in vivo setting was studied in the somatostatin receptor-expressing GOT1 xenograft model. The combination led to a larger decrease in tumour volume relative to monotherapies and the tumour-reducing effect was shown to be synergistic. Using patient-derived tumour cells from eight metastatic SINETs, we could show that ganetespib enhanced the effect of 177Lu-octreotate therapy for all investigated patient tumours. Levels of Hsp90 protein expression were evaluated in 767 SINETs from 379 patients. We found that Hsp90 expression was upregulated in tumour cells relative to tumour stroma in the vast majority of SINETs. We conclude that Hsp90 inhibitors enhance the tumour-killing effect of 177Lu-octreotate therapy synergistically in SINET tumour models and suggest that this potentially promising combination should be further evaluated.

Circulating Tumour Cells (CTCs) are associated with bone metastases in patients with Neuroendocrine Tumours (NET)

2017 ◽  
Author(s):  
Francesca Maria Rizzo ◽  
Alexa Childs ◽  
Dalvinder Mandair ◽  
Mohid S Khan ◽  
Mauro Cives ◽  
...  
Keyword(s):  
Bone Metastases ◽  
Neuroendocrine Tumours ◽  
Tumour Cells ◽  
Circulating Tumour Cells

2389 Detection of SSTR2 and 5 expression in circulating tumour cells from patients with neuroendocrine tumours

2015 ◽  
Vol 51 ◽  
pp. S466-S467
Author(s):  
A. Childs ◽  
C. Vesely ◽  
L. Ensell ◽  
M. Caplin ◽  
C. Toumpanakis ◽  
...  
Keyword(s):  
Neuroendocrine Tumours ◽  
Tumour Cells ◽  
Circulating Tumour Cells
Sign in / Sign up

Export Citation Format

Share Document